Given that heterogeneous tumors express both EGFR and EGFRvIII, and single-target treatment has resulted in tumor tolerance and recurrence in some GBM patients, dual-specific second-generation CAR-NK cells were created and led to a more pronounced progression-free survival in EGFR and EGFRvIII double-positive mouse tumor models [244]. This evidence concerns the gene EGFR and glioblastoma.